Literature DB >> 31534093

Early Operation and Establishment of an Endocarditis Team.

Takahiko Fukuchi1, Hitoshi Sugawara1.   

Abstract

Entities:  

Keywords:  endocarditis team; gram-negative bacilli; prosthetic valve endocarditis; surgery; treatment

Year:  2019        PMID: 31534093      PMCID: PMC7028399          DOI: 10.2169/internalmedicine.3664-19

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


× No keyword cloud information.
To the Editor We read with great interest the article entitled “Prosthetic Aortic Valve Endocarditis” by Ko, et al. in the Internal Medicine advanced publication (1). The authors appropriately applied the imaging study, which was mentioned in the European guidelines (2), but not in the American guidelines (3), for the diagnosis of prosthetic valve infectious endocarditis. We would like to express our appreciation to the authors for leading us physicians to correctly diagnose this emerging infectious disease with proper methods in an era when cardiovascular devices are dramatically increasing. We would like to ask the authors the following two questions: First, both the European and the American guidelines stated that such non-Haemophilus sp, Actinobacillus, Cardiobacterium, Eikenella, Kingella (HACEK) Gram-negative bacilli require cardiac surgery and long-term combination antimicrobial therapy with at least two different classes (2,3). Since some surgeons tend to think that cardiac surgery is contraindicated in elderly patients in the real world (4), we would like to ask how the authors and the medical team treated this patient after two weeks of antibiotic treatment. Second, the European guidelines recommend establishing an “endocarditis team”, including cardiac imaging specialists, when available (2). We would like to know whether an endocarditis team with imaging specialists exists at the author's institute and whether early discussion with the surgical team was successful and constructive, as the guideline stated that this is “mandatory” for the management of all patients with complicated endocarditis (2) because, unfortunately, some discussions among physicians and surgeons remain as far apart as ever. The authors state that they have no Conflict of Interest (COI).
  4 in total

Review 1.  Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Imad M Tleyjeh; Michael J Rybak; Bruno Barsic; Peter B Lockhart; Michael H Gewitz; Matthew E Levison; Ann F Bolger; James M Steckelberg; Robert S Baltimore; Anne M Fink; Patrick O'Gara; Kathryn A Taubert
Journal:  Circulation       Date:  2015-09-15       Impact factor: 29.690

2.  A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease.

Authors:  Bernard Iung; Gabriel Baron; Eric G Butchart; François Delahaye; Christa Gohlke-Bärwolf; Olaf W Levang; Pilar Tornos; Jean-Louis Vanoverschelde; Frank Vermeer; Eric Boersma; Philippe Ravaud; Alec Vahanian
Journal:  Eur Heart J       Date:  2003-07       Impact factor: 29.983

3.  2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).

Authors:  Gilbert Habib; Patrizio Lancellotti; Manuel J Antunes; Maria Grazia Bongiorni; Jean-Paul Casalta; Francesco Del Zotti; Raluca Dulgheru; Gebrine El Khoury; Paola Anna Erba; Bernard Iung; Jose M Miro; Barbara J Mulder; Edyta Plonska-Gosciniak; Susanna Price; Jolien Roos-Hesselink; Ulrika Snygg-Martin; Franck Thuny; Pilar Tornos Mas; Isidre Vilacosta; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

4.  Prosthetic Aortic Valve Endocarditis.

Authors:  Seien Ko; Shunsuke Uno; Shun Kohsaka
Journal:  Intern Med       Date:  2019-07-10       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.